Campus Event Calendar
Event Entry
What and Who
Docking und De Novo Design: How Good are our Predictions
Dr. Martin Stahl
F. Hoffmann-La Roche Ltd.
Talk
AG 1, AG 2, AG 3, AG 4
MPI Audience
Note: We use this to send email in the morning.
Date, Time and Location
Thursday, 14 November 2002
09:15
-- Not specified --
46.1 - MPII
024
Saarbrücken
Abstract
The early phases of commercial drug discovery programs are increasingly
guided by information extracted from three-dimensional structures of the
target proteins whose functions are to be modulated. Docking and De Novo
Design are two complementary techniques for selecting small molecules that
should bind to a protein binding site. Using examples from research and
method development projects at Roche, I will outline the current status in
these fields and discuss key issues for further development.
guided by information extracted from three-dimensional structures of the
target proteins whose functions are to be modulated. Docking and De Novo
Design are two complementary techniques for selecting small molecules that
should bind to a protein binding site. Using examples from research and
method development projects at Roche, I will outline the current status in
these fields and discuss key issues for further development.
Contact
--email hidden
passcode not visible
logged in users only